A New Dawn for CRISPR, Intellia Edits Cells Inside the Body
Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in vivo CRISPR/Cas9 therapy brought good news for everyone as the trials managed to present improvements in a rare inherited liver disorder.
The robust efficacy data was coupled with an encouraging safety profile with no serious adverse events as observed in the first six patients as of day 28. The treatment aims to repair a gene responsible for transthyret...
